ES2113870T3 - Utilizacion de n,n'-bis 3-(etilamino)propil-1,7-heptanodiamina y un agente citotoxico. - Google Patents

Utilizacion de n,n'-bis 3-(etilamino)propil-1,7-heptanodiamina y un agente citotoxico.

Info

Publication number
ES2113870T3
ES2113870T3 ES91121354T ES91121354T ES2113870T3 ES 2113870 T3 ES2113870 T3 ES 2113870T3 ES 91121354 T ES91121354 T ES 91121354T ES 91121354 T ES91121354 T ES 91121354T ES 2113870 T3 ES2113870 T3 ES 2113870T3
Authority
ES
Spain
Prior art keywords
propil
bis
cytotoxic agent
heptanodiamine
ethylamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91121354T
Other languages
English (en)
Inventor
Nellikunja J Prakash
Terry L Bowlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2113870T3 publication Critical patent/ES2113870T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ESTA INVENCION SE REFIERE A LA UTILIZACION DE N, N''-BIS[3-(ETILMINO) PROPIL]-1,7-HEPTANEDIAMINE Y UN AGENTE CITOTOXICO SELECCIONADO DEL GRUPO QUE CONSISTE DE UN ALCALOIDE ANTINEOPLASTICO, UN ANTIBIOTICO ANTINEOPLASTICO, UN ANTIMETABOLITO ANTINEOPLASTICO Y UN COMPLEJO DE COORDINACION ANTINEOPLASTICO PARA LA PREPARACION DE UNA COMPOSICION FARMACEUTICA UTIL PARA EL TRATAMIENTO DE UN PACIENTE QUE SUFRE DE UN ESTADO NEOPLASTICO.
ES91121354T 1990-12-13 1991-12-12 Utilizacion de n,n'-bis 3-(etilamino)propil-1,7-heptanodiamina y un agente citotoxico. Expired - Lifetime ES2113870T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62681490A 1990-12-13 1990-12-13

Publications (1)

Publication Number Publication Date
ES2113870T3 true ES2113870T3 (es) 1998-05-16

Family

ID=24511975

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91121354T Expired - Lifetime ES2113870T3 (es) 1990-12-13 1991-12-12 Utilizacion de n,n'-bis 3-(etilamino)propil-1,7-heptanodiamina y un agente citotoxico.

Country Status (11)

Country Link
EP (1) EP0490380B1 (es)
JP (1) JPH04275233A (es)
KR (1) KR100195423B1 (es)
AT (1) ATE163264T1 (es)
AU (1) AU648846B2 (es)
DE (1) DE69128926T2 (es)
DK (1) DK0490380T3 (es)
ES (1) ES2113870T3 (es)
GR (1) GR3026432T3 (es)
IE (1) IE914331A1 (es)
ZA (1) ZA919695B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0819432B1 (en) * 1996-01-31 2004-03-24 Japan Science and Technology Corporation Antitumor agents comprising as the principal agent compounds containing silicon and nitrogen
US6274561B1 (en) 1997-01-29 2001-08-14 Japan Science & Technology Corp. Antitumor agents comprising as the principal compounds containing silicon and nitrogen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ223340A (en) * 1987-02-03 1991-03-26 Merrell Dow Pharma Polyamine derivatives and pharmaceutical compositions
EP0378146B1 (en) * 1989-01-10 1995-03-29 Merrell Pharmaceuticals Inc. Polyamine derivatives as antineoplastic agents
ZA903804B (en) * 1989-05-23 1991-03-27 Merrell Dow Pharma A method of potentiating cell-mediated immunity utilizing polyamine derivatives

Also Published As

Publication number Publication date
KR920011481A (ko) 1992-07-24
ATE163264T1 (de) 1998-03-15
AU648846B2 (en) 1994-05-05
AU8890791A (en) 1992-06-18
IE914331A1 (en) 1992-06-17
JPH04275233A (ja) 1992-09-30
GR3026432T3 (en) 1998-06-30
KR100195423B1 (ko) 1999-06-15
ZA919695B (en) 1992-09-30
EP0490380A2 (en) 1992-06-17
DK0490380T3 (da) 1998-09-23
DE69128926T2 (de) 1998-06-04
DE69128926D1 (de) 1998-03-26
EP0490380A3 (en) 1993-03-10
EP0490380B1 (en) 1998-02-18

Similar Documents

Publication Publication Date Title
ES2159591T3 (es) Composicion de liberacion controlada.
ES2162319T3 (es) Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer.
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
MX9305248A (es) Compuestos de diarilpiperazinoacetamida.
ES554967A0 (es) Un procedimiento para preparar una formulacion farmaceutica que contiene un 2'3'-didesoxi-nucleosido.
ES2058892T3 (es) Uso de omeprazol como agente antimicrobiano.
ES2074124T5 (es) Composicion en forma de una espuma que contiene acido 5-aminosalicilico para administracion intra-rectal.
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
ATE188119T1 (de) Heilmittel für wunden und hämorrhoiden
AR004510A1 (es) Composiciones que comprenden amoxicilina y clavulanato, procedimientos para su preparacion y el uso de las composiciones para la fabricacion de unmedicamento
ES2080549T3 (es) Medicamentos a base de derivados de polihidroximetileno, procedimiento para su preparacion y empleo.
ES2038650T3 (es) Procedimiento para preparar una composicion farmaceutica que comprende 3'-desoxitimidin-2'-eno-(3'-desoxi-2',3'-dideshidrotimidina) para tratar pacientes infectados con retrovirus.
ATE114974T1 (de) Abgabe von cytotoxischen mitteln.
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
ES2113870T3 (es) Utilizacion de n,n'-bis 3-(etilamino)propil-1,7-heptanodiamina y un agente citotoxico.
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
BR9508021A (pt) Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico
DE3264400D1 (en) Oxazole derivatives, their preparation and use
GR1002576B (el) Φαρμακευτικες συνθεσεις και μια μεθοδος παρασκευης τους.
FR2632525B1 (fr) Application therapeutique de la myeloperoxydase humaine
SE9000624D0 (sv) New use
IL93599A0 (en) Kit and/or composition for the prevention or treatment of aids
NO873934L (no) Saarhelende serotoninantagonistisk forbindelse.
ES2049711T1 (es) Uso de bucilamina para la fabricacion de un medicamento para el tratamiento de la cistinuria.
ES2059615T3 (es) Empleo del derivado de tiazol tiprotimoda para la preparacion de un agente para la terapia de infecciones por virus.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 490380

Country of ref document: ES